1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Alberto Abaterusso
Alberto Abaterusso
Articles (1345) 

Roche's Leukemia Drug Approved for Next Step in Europe

Venclyxto drug gets 'conditional marketing' approval from European Commission

December 11, 2016 | About:

Roche (RHHBY) announced on Dec. 8 that Venclyxto (venetoclax), a drug that is used as therapy in patients chronically affected with lymphocytic leukemia, has been authorized by the European Commission, achieving the “conditional marketing.”

The Swiss global healthcare company’s announcement specifically refers to the following two groups of chronically patients affected with lymphocytic leukemia:

  1. The first group is composed of patients in whom the highest portion of one of the two chromosomes number 17 is lacking, which is a very small portion and is labelled as p, or whose gene TP53 is altered. On these patients, a previous therapy based on the blockage of the protein B, which is considered to be responsible in a process called apoptosis that is the ‘programmed cell death’, was either unsuccessful or unfeasible.
  2. The second group is composed of patients who don’t show the genetic particularities of the aforementioned group. On these patients, a previous therapy based on the blockage of the protein B and a prior chemotherapy together with immunotherapy, were both unsuccessful.

Venclyxto is an organic combination of low molecular weight that inhibits the B-cell lymphoma-2 (or BCL-2) protein. The researchers correlate this protein with the failure of therapy because it was found in high percentages in chronic CLL patients’ blood. Therefore, the researchers believe that blocking the BCL-2, the signalling system that brings cells suicide may be repaired and therefore the outcome for patients with chronic lymphocytic leukemia may be improved.

The European Medicines Agency says that “applicants may be granted a conditional marketing authorisation for such medicines where the benefit of immediate availability outweighs the risk of less comprehensive data than normally required.”

Furthermore, patients chronically affected with lymphocytic leukemia and who either show anomalies in one of the two chromosomes number 17 or on whom a previous therapy was unsuccessful, “are in particular need of new treatment options as the disease is more difficult to treat and further options are limited,” the company says.

“Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from cells that become certain white blood cells (called lymphocytes) in the bone marrow. The cancer (leukemia) cells start in the bone marrow but then go into the blood.

In chronic leukemia, the cells can mature partly but not completely. These cells may look fairly normal, but they are not. They generally do not fight infection as well as normal white blood cells do. The leukemia cells survive longer than normal cells, and build up, crowding out normal cells in the bone marrow. Chronic leukemias can take a long time before they cause problems, and most people can live for many years. But chronic leukemias are generally harder to cure than acute leukemias.” -cancer.org

Roche (RHHBY) is advancing Venclyxto in cooperation with AbbVie (NYSE:ABBV).

Roche Group, through one of its subsidiaries, Genentech, together with AbbVie, markets the medication Venclexta/Venclyxto in the U.S. under the name of Venclexta. AbbVie has also the right to market Venclyxto outside the U.S.

Roche closed at $27.86 Friday, up 79 cents or 2.88% from the previous close. The stock lost 19.18% year to date.

Disclosure: I have no positions in any stock mentioned in this article.

Start a free seven-day trial of Premium Membership to GuruFocus. 

About the author:

Alberto Abaterusso
If somebody asks what being a value investor means, Alberto Abaterusso would answer, “The value investor is not just the possessor of the security that represents the company, but he is the owner of that company. As an owner of the company the value investor is actively involved in the dynamics of that company and his first concern is how to have sales progressively growing. Also, the value investor is probably one of the most demanding persons in the world concerning sales.”

Abaterusso is a freelance writer based in The Netherlands. He primarily writes about gold, silver and precious metals mining stocks. His articles have also been widely linked by popular sites, including MarketWatch, Financial Times, 24hGold, Investopedia, Financial.org, CNBS, MSN Money, Zachs, Reuters and others. Alberto holds an MBA from Università degli Studi di Bari (Italy), Aldo Moro.

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by Alberto Abaterusso


User Generated Screeners


TarunEarngs gth, buybacks 0
TarunEarngs gth, buybacks
TarunP/S, buybacks
TarunP/E, buybacks
scott.hollenbergScreen 1
DANGORDONROC ROE 1YR RETURN
pbarker46Buying & selling guidlines
alexjestestje1
alexjestestje
5dmeyerLow pe
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK